Here's a look at every­thing Mer­ck­'s BD group has done in the past 12 years, il­lus­trat­ing why the Seat­tle Ge­net­ics deal stands out

A lit­tle over 3 years ago, Mer­ck splashed in­to a li­cens­ing deal with As­traZeneca cov­er­ing their block­buster Lyn­parza fran­chise with $1.6 bil­lion in cash up­front. Un­til to­day, that was by far the biggest sin­gle col­lab­o­ra­tion that Mer­ck has seen in the past 12 years.

I asked Chris Doko­ma­ji­lar at Deal­For­ma to up­date the charts on Mer­ck, and as you can see be­low, the deal that the phar­ma gi­ant just con­ceived with Seat­tle Ge­net­ics on a LIV1 ADC — with an­oth­er $1.6 bil­lion for an up­front and eq­ui­ty — dwarfs any­thing else out there that reg­is­tered on the ex­per­i­men­tal side since 2008.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER